CNS and Dose-Reduction Events After Abiraterone/Prednisone in mCRPC
July 19th 2016
Ajay S. Behl, PhD, Janssen Pharmaceuticals, discusses a study examining the central nervous system (CNS) and dose-reduction events in patients with prostate cancer following treatment with abiraterone acetate (Zytiga) plus prednisone.